Dr. Alison McInnes is Vice President, Scientific Affairs at Osmind. She is a nationally recognized expert in psychiatry and mood and anxiety disorders, having specialized in treating refractory disease for over a decade. She is additionally an expert in ketamine treatment and psychedelic medicine.
‍
She founded and served as Medical Director for Kaiser Permanente's ketamine infusion therapy program for a number of years. She was previously an Associate Professor of Psychiatry at Mount Sinai School of Medicine for 8 years where she ran a lab in psychiatric genetics, and was also an adjunct clinical professor at UCSF.
‍
Dr. McInnes is regularly invited to speak at national and international conferences and is asked to consult for biopharmaceutical companies working at the cutting edge of neuropsychiatry. She is a member of the American College of Neuropsychopharmacology and has authored two important papers describing outcomes of ketamine infusion therapy in the largest real-world data sets examined to date. Other research projects include adherence and response prediction to ketamine and related compounds in collaboration with the Osmind data scientist team. She is a member of the American Psychiatric Association (APA) and is expert faculty for the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3). In her current clinical practice, she focuses on treatment-resistant mood disorders and complex cases.
‍
Dr. McInnes received Bachelor’s and Master’s degrees from Stanford University and her MD from Columbia University.
‍
She completed residency at UCSF and research at the VA Research Fellowship and Howard Hughes Physician Research Fellowship in Psychiatric Genetics at UCSF.